2023
Determinants of overall survival in patients with metastatic uveal melanoma
Demkowicz P, Pointdujour‐Lim R, Miguez S, Lee Y, Jones B, Barker C, Bosenberg M, Abramson D, Shoushtari A, Kluger H, Francis J, Sznol M, Bakhoum M. Determinants of overall survival in patients with metastatic uveal melanoma. Cancer 2023, 129: 3275-3286. PMID: 37382208, PMCID: PMC11149607, DOI: 10.1002/cncr.34927.Peer-Reviewed Original ResearchMeSH KeywordsFemaleHumansImmune Checkpoint InhibitorsIpilimumabMelanomaRetrospective StudiesUveal NeoplasmsConceptsAnti-PD-1 therapyMetastatic uveal melanomaDeath hazard ratioImmune checkpoint inhibitorsOverall survivalHazard ratioUveal melanomaSurvival outcomesFemale sexCheckpoint inhibitorsECOG scoreValidation cohortEastern Cooperative Oncology Group performance status scaleGood baseline performance statusMetastatic uveal melanoma patientsMetastatic UM patientsImproved overall survivalMedian overall survivalBaseline performance statusBetter survival outcomesImproved survival outcomesPotential of immunotherapyWorse survival outcomesImmune checkpoint therapyKaplan-Meier analysisValidation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma
Miguez S, Lee R, Chan A, Demkowicz P, Jones B, Long C, Abramson D, Bosenberg M, Sznol M, Kluger H, Goldbaum M, Francis J, Pointdujour-Lim R, Bakhoum M. Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma. Ophthalmology 2023, 130: 598-607. PMID: 36739981, PMCID: PMC10619207, DOI: 10.1016/j.ophtha.2023.01.020.Peer-Reviewed Original ResearchConceptsMetastasis-free survivalRisk of metastasisClass 2 tumorsAdditional prognostic valueRate of metastasisPrognostic usefulnessTumor sizeTumor characteristicsPrognostic valueUveal melanomaGene expression profile testingMemorial Sloan-Kettering Cancer CenterGEP classificationCox hazard regression analysisYale-New Haven HospitalHazards regression analysisGene expression profiling testsNew Haven HospitalClass 1 tumorsGEP class 2Class 1AMean followTumor thicknessCancer CenterSurveillance protocol
2020
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: e000341. PMID: 32209601, PMCID: PMC7103823, DOI: 10.1136/jitc-2019-000341.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansMaleMelanomaMiddle AgedNeoplasm MetastasisSkin NeoplasmsSurvival AnalysisUveal NeoplasmsConceptsCheckpoint inhibitorsOverall survivalMetastatic melanomaPrimary tumorLocal therapyCutaneous melanomaAnti-PD-1 antibodyAggressive multidisciplinary approachCutaneous primary tumorPrimary tumor histologyMedian overall survivalSingle institutional experienceRare melanoma subtypeMedian OSMetastatic diseaseProgressive diseaseAcral skinComplete responsePD-1PD-L1Uveal tractTumor histologyCombination therapyCTLA-4Longer survival
2017
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. British Journal Of Cancer 2017, 116: 432-440. PMID: 28103611, PMCID: PMC5318966, DOI: 10.1038/bjc.2016.419.Peer-Reviewed Original ResearchConceptsObjective response rateStable diseaseWeek 12Metastatic melanomaEvaluable patientsDiscontinuation trialUveal melanomaCommon grade 3/4 adverse eventsGrade 3/4 adverse eventsTreatment-related deathsMedian overall survivalProgression-free survivalResponse Evaluation CriteriaCohort of patientsStudy days 1Further clinical investigationPhase IIAbdominal painDiverticular perforationPrimary endpointAdverse eventsOverall survivalTarget lesionsClinical activityClinical investigation
2015
Melanoma: Clinical Presentations
Kibbi N, Kluger H, Choi JN. Melanoma: Clinical Presentations. Cancer Treatment And Research 2015, 167: 107-129. PMID: 26601860, DOI: 10.1007/978-3-319-22539-5_4.Peer-Reviewed Original ResearchConceptsNon-cutaneous lesionsUpper gastrointestinal mucosaMalignant skin lesionsGenital mucosaUveal tractClinical presentationDistant metastasisCutaneous lesionsPattern of spreadTypical presentationGastrointestinal mucosaSkin lesionsOral cavityMucosal surfacesMalignant cellsMelanomaRed lesionsLesionsRegional spreadBasal layerMucosaMelanocytesPresentationLeptomeningesMetastasis
2012
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker J, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics 2012, 44: 1006-1014. PMID: 22842228, PMCID: PMC3432702, DOI: 10.1038/ng.2359.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCase-Control StudiesDNA Mutational AnalysisExomeFemaleGene FrequencyGenetic Predisposition to DiseaseHumansMaleMelanomaMiddle AgedModels, MolecularMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Rac1 GTP-Binding ProteinSequence Analysis, DNASkin NeoplasmsUveal NeoplasmsConceptsSun-exposed melanomasDriver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
Mehnert JM, Kluger HM. Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. Current Oncology Reports 2012, 14: 449-457. PMID: 22723080, PMCID: PMC4447200, DOI: 10.1007/s11912-012-0249-5.Peer-Reviewed Original ResearchConceptsDriver mutationsSpecific patient subsetsPotential therapeutic strategyPatient subsetsSomatic driver mutationsMetastatic melanomaBedside studiesUveal melanomaTherapeutic strategiesBRAFV600E mutationMalignant transformationMelanomaMolecular classificationDevelopment of inhibitorsHuman samplesMutationsMolecular biologyBRAFDisease
2011
Molecular Alternations in Uveal Melanoma
Materin MA, Faries M, Kluger HM. Molecular Alternations in Uveal Melanoma. Current Problems In Cancer 2011, 35: 211-224. PMID: 21911184, DOI: 10.1016/j.currproblcancer.2011.07.004.Peer-Reviewed Original Research